Personalised cancer vaccines: New strategies in cancer therapy

Research at the Clinical and Translational Research Centre shows how vaccines are being investigated in combination with standard treatments

Personalised cancer vaccines are becoming increasingly important in oncology. A recent review emphasises that their full potential is being investigated not in isolation, but in combination with standard therapies such as chemotherapy, radiotherapy or immune checkpoint inhibitors.

The vaccines aim to specifically sensitise the immune system to tumour cells and support the response to existing therapies. At the same time, standard treatments can modulate the immune response, for example by releasing antigens or influencing the tumour microenvironment.

Lana Kandalaft, Chief of Clinical and Translational Research, and her team at the Swiss Medical Network are involved in the research, testing new strategies to integrate personalised vaccines into multimodal treatment approaches on a scientific basis.

Advances in genomics, AI-assisted antigen selection and new platforms such as mRNA, peptides or lipid nanoparticles are driving this research forward. The studies aim to expand scientific knowledge and better understand the potential applications of personalised cancer vaccines.

Personalized cancer vaccines and their integration with standard of care modalities - ScienceDirect